Cardiff Oncology Inc. (CRDF) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cardiff Oncology Inc. (CRDF)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.30

-0.17 (-4.90%)

At close: Jan 14, 2025, 3:59 PM

3.30

0.02%

Pre-market Jan 15, 2025, 06:56 AM EST

undefined% (undefined)

Bid	3.3
Market Cap	219.48M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.95
PE Ratio (ttm)	-3.47
Forward PE	n/a
Analyst	Buy

Ask	3.54
Volume	801,670
Avg. Volume (20D)	2,113,286
Open	3.54
Previous Close	3.47
Day's Range	3.28 - 3.57
52-Week Range	1.44 - 6.42
Beta	undefined

About CRDF

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevac...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 27, 2004

Employees 31

Stock Exchange NASDAQ

Ticker Symbol CRDF

Website https://www.cardiffoncology.com

Analyst Forecast

According to 3 analyst ratings, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 203.08% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Cardiff Oncology Inc. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $73.00K, reflecting a -53.21% YoY shrinking and earnings per share of -0.26, making a 23.81% increase YoY.

Why Price Moved

1 month ago · Source

+19.88%

Cardiff Oncology shares are trading higher after P... Unlock content with Pro Subscription

1 month ago · Source

+54.92%

Cardiff Oncology shares are trading higher after the company announced the initial data from its CRDF-004 Phase 2 trial evaluating Onvansertib.

News

1 month ago · seekingalpha.com

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational im...

1 month ago · seekingalpha.com

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when...

1 month ago · zacks.com

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.

1 month ago · seekingalpha.com

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Cardiff Oncology's Phase 2 trial data for Onvansertib in metastatic colorectal cancer shows dose-related outperformance of standard care, with a combined ORR of 57% versus 33% in the control arm. The ...

2 months ago · zacks.com

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.